SCHEMBL397063

SCHEMBL397063

CSc1ccc(-c2ccccc2N)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
HSD17B10 Q99714 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.48
PTGS2 P35354 5/20 0.43
PTGS1 P23219 3/20 0.40
DHFR P00374 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
KDM4E B2RXH2 2/20 0.37
GAA P10253 2/20 0.37
HPGD P15428 2/20 0.37
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.37
CYP3A4 P08684 1/20 0.36
ALOX15 P16050 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
FFAR1 O14842 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36
S1PR1 P21453 1/20 0.36
GLA P06280 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1269993 0.83 ALDH1A1 (0.62) ALDH1A1HSD17B10L3MBTL1DHFRSMN1; SMN2
SCHEMBL6480845 0.82 ALDH1A1 (0.83) ALDH1A1HSD17B10L3MBTL1DHFRSMN1; SMN2
SCHEMBL6247727 0.80 PTGS2 (0.57) ALDH1A1HSD17B10PTGS2PTGS1GAA
SCHEMBL31264295 0.79 ALDH1A1 (0.79) ALDH1A1HSD17B10L3MBTL1DHFRSMN1; SMN2
SCHEMBL3791339 0.79 ALDH1A1 (0.64) ALDH1A1HSD17B10L3MBTL1DHFRSMN1; SMN2
SCHEMBL3787091 0.79 ALDH1A1 (0.52) ALDH1A1HSD17B10L3MBTL1DHFRSMN1; SMN2
SCHEMBL3781022 0.79 ALDH1A1 (0.52) ALDH1A1HSD17B10L3MBTL1DHFRSMN1; SMN2
SCHEMBL13211667 0.78 PTGS2 (0.46) ALDH1A1PTGS2PTGS1SMN1; SMN2KDM4E
SCHEMBL24899907 0.78 CYP1A2 (0.40) ALDH1A1HSD17B10PTGS2CYP3A4
SCHEMBL2425694 0.78 ALDH1A1 (0.52) ALDH1A1HSD17B10L3MBTL1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2507230-B1 INSECTICIDAL COMPOUNDS BASED ON ISOXAZOLINE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2018-01-17 EP claimed
US-12043600-B2 Microbiocidal compounds SYNGENTA CROP PROTECTION AG (CH) 2024-07-23 US disclosed
US-12018030-B2 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors VALO HEALTH, INC. (US) 2024-06-25 US disclosed
CN-112789265-B Microbiocidal compounds 先正达农作物保护股份公司 2024-03-08 CN disclosed
US-11882834-B2 Microbiocidal thiazole derivatives SYNGENTA PARTICIPATIONS AG (CH) 2024-01-30 US disclosed
CN-106998682-B Pesticide formulations with physical mode of action ICB制药公司 2023-10-27 CN disclosed
CN-111303116-B Microbiocidal heterobicyclic derivatives 先正达参股股份有限公司 2023-10-10 CN disclosed
CN-111406055-B Microbiocidal thiazole derivatives 先正达参股股份有限公司 2023-09-22 CN disclosed
US-11744246-B2 Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide SYNGENTA PARTICIPATIONS AG (CH) 2023-09-05 US disclosed
CN-110382492-B Microbiocidal oxadiazole derivatives 先正达参股股份有限公司 2023-07-14 CN disclosed
US-20090246820-A1 COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH VERTEX PHARMACEUTICALS INCORPORATED 2009-10-01 US disclosed
US-20090227797-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-09-10 US disclosed
US-7495103-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-02-24 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed
US-20080071095-A1 Cystic fibrosis transmembrane conductance VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-03-20 US disclosed
US-20060074075-A1 including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders VERTEX PHARMACEUTICALS INCORPORATED 2006-04-06 US disclosed
EP-0783486-B1 NOVEL PROSTAGLANDIN SYNTHASE INHIBITORS DU PONT PHARM CO (US) 1999-10-13 EP disclosed
US-5932586-A ANTIINFLAMMATORY AGENTS; ANTIPYRETICS DUPONT PHARMACEUTICALS COMPANY (US) 1999-08-03 US disclosed
EP-0783486-A1 NOVEL PROSTAGLANDIN SYNTHASE INHIBITORS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-07-16 EP disclosed
US-5593994-A ANTIINFLAMMATORY AGENTS THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12043600-B2 Microbiocidal compounds MPO, MSR1, PRF1 ALDH1A1 500/4885HSD17B10 1282/4885L3MBTL1 1317/4885
US-11882834-B2 Microbiocidal thiazole derivatives MSR1, TLR1, IFNG ALDH1A1 392/4885HSD17B10 1217/4885L3MBTL1 844/4885
US-20090227797-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 ALDH1A1 2165/4885HSD17B10 1468/4885L3MBTL1 3552/4885
US-12018030-B2 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors USP7, UBA7, UBXN1 ALDH1A1 2705/4885HSD17B10 4176/4885L3MBTL1 1217/4885
US-11744246-B2 Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide PHF20, FUCA1, ZP1 ALDH1A1 1241/4885HSD17B10 68/4885L3MBTL1 3605/4885
US-20080071095-A1 Cystic fibrosis transmembrane conductance CFTR, ABCB1, ABCC1 ALDH1A1 2651/4885HSD17B10 1678/4885L3MBTL1 3929/4885
US-20060074075-A1 including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), used for treating genetic disorders; respiratory system disorders CFTR, ABCC4, ABCC2 ALDH1A1 2221/4885HSD17B10 1602/4885L3MBTL1 3693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.